Literature DB >> 27476341

Significant Association of the RNF213 p.R4810K Polymorphism with Quasi-Moyamoya Disease.

Takaaki Morimoto1, Yohei Mineharu2, Hatasu Kobayashi3, Kouji H Harada4, Takeshi Funaki5, Yasushi Takagi5, Nobuyuki Sakai6, Susumu Miyamoto5, Akio Koizumi4.   

Abstract

BACKGROUND: Quasi-moyamoya disease is an angiographical moyamoya disease equivalent accompanied by known underlying diseases. Mysterin/RNF213 is a major susceptibility gene for moyamoya disease, of which the p.R4810K variant is a founder polymorphism. The genetics of quasi-moyamoya disease is poorly understood, therefore, this study investigated a potential association between the p.R4810K polymorphism and quasi-moyamoya disease.
METHODS: Genotyping of the p.R4810K variant was performed on 18 quasi-moyamoya disease cases and 91 controls, who visited Kyoto University Hospital or Kobe City Medical Center, Japan, between 2006 and 2015.
RESULTS: The p.R4810K variant was found in 12 of 18 quasi-moyamoya disease patients. The frequency of p.R4810K carriers was significantly higher in quasi-moyamoya disease cases than in controls (66.7% versus 2.2%, odds ratio 89.0, 95% confidence interval: 19.2-669.4).
CONCLUSIONS: Our data showed that the RNF213 p.R4810K polymorphism was significantly associated with quasi-moyamoya disease.
Copyright © 2016 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Moyamoya disease; RNF213; epidemiology; genetics

Mesh:

Substances:

Year:  2016        PMID: 27476341     DOI: 10.1016/j.jstrokecerebrovasdis.2016.07.004

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  7 in total

1.  Rare RNF213 variants in the C-terminal region encompassing the RING-finger domain are associated with moyamoya angiopathy in Caucasians.

Authors:  Stéphanie Guey; Markus Kraemer; Dominique Hervé; Thomas Ludwig; Manoëlle Kossorotoff; Françoise Bergametti; Jan Claudius Schwitalla; Simone Choi; Lucile Broseus; Isabelle Callebaut; Emmanuelle Genin; Elisabeth Tournier-Lasserve
Journal:  Eur J Hum Genet       Date:  2017-06-21       Impact factor: 4.246

2.  When and why is surgical revascularization indicated for the treatment of moyamoya syndrome in patients with RASopathies? A systematic review of the literature and a single institute experience.

Authors:  Marcello Scala; Pietro Fiaschi; Valeria Capra; Maria Luisa Garrè; Domenico Tortora; Marcello Ravegnani; Marco Pavanello
Journal:  Childs Nerv Syst       Date:  2018-05-24       Impact factor: 1.475

3.  Moyamoya angiopathy in PHACE syndrome not associated with RNF213 variants.

Authors:  Jeffrie Hadisurya; Stephanie Guey; Lou Grangeon; Dagmar Wieczorek; Michaelle Corpechot; Jan Claudius Schwitalla; Markus Kraemer
Journal:  Childs Nerv Syst       Date:  2019-04-29       Impact factor: 1.475

4.  RNF213 variants in a child with PHACE syndrome and moyamoya vasculopathy.

Authors:  Kala F Schilter; Jack E Steiner; Wendy Demos; Mohit Maheshwari; Jeremy W Prokop; Elizabeth Worthey; Beth A Drolet; Dawn H Siegel
Journal:  Am J Med Genet A       Date:  2017-07-07       Impact factor: 2.802

Review 5.  Influence of Inflammatory Disease on the Pathophysiology of Moyamoya Disease and Quasi-moyamoya Disease.

Authors:  Takeshi Mikami; Hime Suzuki; Katsuya Komatsu; Nobuhiro Mikuni
Journal:  Neurol Med Chir (Tokyo)       Date:  2019-07-06       Impact factor: 1.742

6.  RNF213 variant in a patient with Legius syndrome associated with moyamoya syndrome.

Authors:  Giulia Romanisio; Cristina Chelleri; Marcello Scala; Gianluca Piccolo; Barbara Carlini; Laura Gatti; Valeria Capra; Federico Zara; Anna Bersano; Marco Pavanello; Patrizia De Marco; Maria Cristina Diana
Journal:  Mol Genet Genomic Med       Date:  2021-05-03       Impact factor: 2.183

7.  Observation of p.R4810K, a Polymorphism of the Mysterin Gene, the Susceptibility Gene for Moyamoya Disease, in Two Female Japanese Diabetic Patients with Familial Partial Lipodystrophy 1.

Authors:  Masanori Iwanishi; Choka Azuma; Yuji Tezuka; Yukako Yamamoto; Jun Ito-Kobayashi; Miki Washiyama; Toru Kusakabe; Shingo Kikugawa
Journal:  Intern Med       Date:  2020-10-15       Impact factor: 1.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.